Browse diseases

…dance (p < 0.001). MAIT cells were lower in non-small cell lung cancer patients with high PD-L1 status by IHC (TPS > 50%; p < 0.001). …

…fective allogeneic platform for CAR-based immunotherapy in both cancer and autoimmune diseases, providing a strong foundation for furt…

…TRP-2, were generated using an established B16 melanoma-induced vitiligo model. 4 5 To determine Trm requirement for persistent antigen …

… IL-27, NO, VIP, VDR, TRAIL, and the Ca types were NSCLC, SCLC, HNSCC, Melanoma, GBM, Pancreatic, Bladder, Gastric, Prostate, Breast,…

…41 per cohort) with recurrent or metastatic non-small cell lung cancer (NSCLC), melanoma, endometrial cancers, or head and neck squamo…

… (PD-1) receptor on immune cells is a key mechanism employed by cancer cells to evade the immune response. Regardless of the success o…

…s provide a generalizable framework for optimizing personalized cancer vaccine design and predicting frequencies of T cell responses e…

…al therapy, we conjugated cs21 to a CD45 targeting antibody. In B16F10 melanoma, αCD45-cs21 induced robust pSTAT3 in CD45+ cells in the tumor d…

…n samples from patients with localized, muscle-invasive bladder cancer who received neoadjuvant anti-PD-L1 checkpoint inhibitor therap…

…ibodies, CAR-T, tumor-infiltrating lymphocytes, and therapeutic cancer vaccines. However, in most cases, these approaches involve time…

…s model support its potential for preclinical and translational cancer immunotherapy research.…

…ith immune-related adverse effects in ICI-treated patients with cancer. Journal for ImmunoTherapy of Cancer. 2025;13:e012012. https://…